Kamada Secures $25 Million Supply Agreement for KAMRAB® and VARIZIG®

Kamada Secures Major Supply Agreement in Latin America

REHOVOT, Israel and HOBOKEN, N.J. – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global leader in biopharmaceuticals with a renowned portfolio aimed at rare and serious conditions, proudly announces its latest achievement: securing a contract with an influential international organization.

Contract Overview

This contract pertains to the supply of two of Kamada's leading products, KAMRAB® and VARIZIG®, for a term extending from 2025 to 2027. The total projected revenue from this agreement is estimated to be around $25 million. Furthermore, the portions allocated to the fiscal year 2025 have been included in the company's recently revealed revenue guidance for that year.

Implications of the New Agreement

Amir London, Chief Executive Officer of Kamada, expressed great enthusiasm regarding this substantial agreement. He remarked that it reaffirms the global standing of their specialty immunoglobulin portfolio and bolsters the company's anticipated multi-year growth trajectory. Winning this tender exemplifies the significant commercial opportunities for Kamada’s diverse product line beyond North America.

Product Details

KAMRAB and VARIZIG are key assets in Kamada's specialty immune globulin offerings. Specifically, KAMRAB is used for the passive prevention of rabies in individuals who may have been exposed to rabid animals. In contrast, VARIZIG serves to mitigate the severity of chickenpox in vulnerable groups, such as immunocompromised patients.

About KAMRAB®

KAMRAB is a human rabies immune globulin designed for immediate post-exposure prophylaxis to protect against rabies infection. This product must be administered alongside a full rabies vaccine course to ensure top effectiveness.

Safety Profile of KAMRAB

While KAMRAB is lifesaving, it does carry some risks. Individuals may experience severe hypersensitivity reactions, including anaphylaxis. IgA-deficient patients must be particularly cautious, and availability of epinephrine is essential for immediate treatment of any severe allergic incidents. Understanding the immunological impacts, such as potential interferences with live attenuated vaccines, is crucial for providers.

About VARIZIG®

VARIZIG is categorized as Varicella Zoster Immune Globulin (Human) and is integral for high-risk patients requiring post-exposure prophylaxis against chickenpox. It is particularly vital for populations such as immunocompromised children and pregnant women to lessen the severity of the disease.

Safety Financials

As with any medication, VARIZIG must be administered with caution. There’s a risk of severe reactions in susceptible individuals, including those with known hypersensitivity. Monitoring for thrombotic events during treatment is advisable. The product’s safety profile is taken seriously and underscores the need for careful patient selection.

Kamada’s Broader Business Strategy

Kamada Ltd. remains dedicated to addressing rare and serious health conditions with innovative solutions. The company continues to expand its offerings, including six FDA-approved plasma-derived products, and has an impressive distribution network in more than 30 countries globally. Kamada is poised for significant growth, fueled by a commitment to high-quality production and the enhancement of its innovative development pipeline.

Investment in Research and Development

Alongside its commercial successes, Kamada actively invests in research to introduce new candidates into its product lineup. The company is advancing its inhaled AAT therapy aimed at treating AAT deficiency and is currently engaged in the pivotal Phase 3 InnovAATe clinical trial to evaluate this groundbreaking treatment.

Frequently Asked Questions

What is the purpose of the new supply agreement for Kamada?

The new agreement allows Kamada to supply KAMRAB® and VARIZIG® in Latin America, aiming for approximately $25 million over three years.

What are KAMRAB® and VARIZIG® used for?

KAMRAB is used for preventing rabies exposure, while VARIZIG is indicated for preventing severe chickenpox in at-risk patients.

What safety precautions should be taken with KAMRAB®?

Patients should be monitored for severe hypersensitivity reactions, and it is essential to have treatments available for such risks.

How does Kamada's distribution model work?

Kamada distributes its products directly and through strategic partners in over 30 countries, enhancing global access to critical healthcare solutions.

What is next for Kamada in research and development?

Kamada is focused on advancing new products, particularly an inhaled therapy for AAT deficiency, demonstrating its commitment to addressing unmet medical needs.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.